Category: Blog

Michael Greve Doubles Down

Michael Greve, founder of the Forever Healthy Foundation and owner of Kizoo Technology Ventures, announced today that he will make an additional €300 million ($361m USD) available to launch new rejuvenation biotechnology startups and support the clinical translation of therapies designed by Kizoo’s existing portfolio of companies.

Read More »

Defeating Aging by 2036

SRF’s Chief Science Officer, Dr. Aubrey de Grey, recently estimated a 50% chance that aging could be brought under medical control in as little as 15 years’ time. In a new interview with NextBigFuture, Dr. de Grey explains how recent developments – including the global response to the COVID-19 pandemic – contributed to that prediction.

Read More »
Featured

SRF Masks Available

At the end of 2020, we invited all our supporters to submit designs for an official SRF mask. As well as being worn by our staff, these masks are now available – while supplies last – to anyone who’d like to support our work to end age-related disease and disability.

Read More »

WebMD Feature: Is There a Cure for Aging?

“I think there is at least a 50/50 chance that most people alive today will live to 1,000 years old.” In a new video produced by WebMD.com, Dr. Aubrey de Grey discusses emerging medical technologies that could not only pause aging, but reverse it, in the surprisingly near future.

Read More »

Enriching Mitochondria

The MitoSENS team has recently published a new protocol which enables researchers to isolate mitochondria from mammalian cells more efficiently and scalably than any prior technique, using only readily available and economical reagents and equipment.

Read More »
Featured

Undoing Aging is rescheduled to May 26-28, 2022

At the end of each year, SRF launches our final fundraising campaign – the aptly named End of Year Campaign – to encourage our donors to donate during the most giving time of year. This year, matching funds from Michael Antonov and a team of other supporters helped you to smash through our original goal.

Read More »

The Neuroprotector’s Dilemma: A Potential Neuroprotective Agent with a Janus Face

Rejuvenation of the aging brain will require the integrated application of several core rejuvenation biotechnologies, including notably those that remove intra- and extraneuronal aggregates implicated in neurodegenerative aging and mature cell therapy. Numerous aggregate-clearing rejuvenation biotechnologies are now in human trials, whereas mature cell therapy for the brain is a more challenging goal and will not be available for some time. In this context, an alternative approach to maintaining the viability of aging neurons could complement aggregate-clearing therapies to preserve neurons until neural replacement and reinforcement matures. In this post we explore the potential of one recently-emerged approach: inhibition of the unfolded protein response (UPR).

Read More »

Unbinding the Mummies: Human Testing of Rejuvenation Biotechnology Targeting α-Synuclein Begins

Aggregates of the neuronal membrane protein α-synuclein accumulate in the aging brain and are implicated in the non-motor symptoms of Parkinson’s disease and related disorders, as well as subtler age-related dysfunction of the autonomic and peripheral nervous system. Preclinical evidence demonstrates that immunotherapeutic clearance of these aggregates in transgenic animals rescues Parkinson’s-like behavioral and cognitive dysfunction. With support from a major Parkinson’s research and advocacy charity, an Austrian biotech firm has advanced a first-in-class rejuvenation biotechnology targeting α-synuclein aggregates into Phase I clinical trials.

Read More »

New and Better Clinical Trials for Rejuvenation Biotechnologies

The need for disease-modifying therapies in Alzheimer’s disease, and the strength of the case for aggregated beta-amyloid as a target, have recently driven substantial regulatory reform and innovations in clinical trial design to open up the path for faster and more effective human testing and approval of novel Alzheimer’s therapeutics. The first fruits of these changes are a series of large, late-stage clinical trials of immunotherapies targeting the removal of beta-amyloid from the brain. These reforms and precedents open up the path for human testing and approval of future rejuvenation biotechnologies.

Read More »

First Glimpse of Thymic Rejuvenation

Engineering of new thymus tissue is a key rejuvenation biotechnology, to prevent or reverse the dramatic rise in morbidity and mortality from infectious disease that begins in the seventh decade of life. SENS Research Foundation is supporting thymus engineering research at the Wake Forest Institute of Regenerative medicine. In an important first, researchers at UCSF have derived a simple thymus-like tissue transplant that gave promising signs of restoring the ability to help form mature T-cells.

Read More »

Aging, and the Cure of the Diseases of Aging

We’ve all heard the terminology. “Age-related disease.” “The diseases of aging.” “The diseases of old age.” But what do we mean by them? What is the connection between aging and heart disease, or cancer, or Alzheimer’s? And how is SENS Research Foundation targeting that connection to prevent and cure these diseases?

Read More »

Cell Reprogramming Leaps Ahead: First Transplant of Primate Induced Pluripotent Cell-Derived Neurons into Donor Brain

“Reprogramming” of adult differentiated cells into pluripotent stem cells is an exciting method in biology that holds enormous promise for rejuvenation biotechnology. Now, for the first time, Dr. Su-Chun Zhang and coworkers at the University of Wisconsin-Madison have successfully generated neurons from reprogrammed nonhuman primate cells, transplanted them back into the same animal’s brain, and seen them successfully and cleanly integrate into the local tissue.

Read More »

Project: Break Aging Arteries Free

SENS Research Foundation has established a new research center at Cambridge University and a collaboration with scientists at Yale University. The mission: develop new therapies to repair a critical form of molecular damage that drives the slow stiffening of the arteries with age. Such rejuvenation biotechnologies could prevent such deadly and disabling diseases of aging as stroke and kidney disease.

Read More »

“Accelerated Aging:” Inspiration Beyond Equivocation

The preliminary results of a clinical trial for a disease of “premature aging” – Hutchinson-Gilford Progeria Syndrome (HGPS) – are hopeful and inspiring. However, they cannot directly inform the development of rejuvenation biotechnologies; although the symptoms of HGPS are similar to those observed in aging, there is no evidence to suggest that the underlying mechanism is pathologically significant in those not afflicted with the disease.

Read More »

Use of this Web site constitutes acceptance of the Terms of Use and Privacy Policy.

© 2024 SENS Research Foundation – ALL RIGHTS RESERVED

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can

SENS Research Foundation Audience Survey

And follow the link at the end to WIN!: